Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Open-label Trial of BI 3011441 in Japanese Patients With NRAS/KRAS Mutation Positive Advanced, Unresectable or Metastatic Refractory Solid Tumours

NCT04742556 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT04742556
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04742556 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Open-label Trial of BI 3011441 in Japanese Patients With NRAS/KRAS Mutation Positive Advanced, Unresectable or Metastatic Refractory Solid Tumours
Lead sponsor
Boehringer Ingelheim
Phase
Phase 1
Overall status
Completed
Start date
March 15, 2021
Completion date
October 20, 2022
Enrollment
15 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors, kras mutation